EXPAREL IPSA Block in Knee Arthroplasty

Part of paid clinical trials in Germantown, Tennessee.

Sponsor
Campbell Clinic
Study ID
NCT06619340
Phase
PHASE4
Status
Enrolling By Invitation

Conditions

  • Osteo Arthritis Knee
  • Pain, Postoperative

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Exparel — DRUG
    20 milliliter (mL) EXPAREL with 20mL bupivacaine hydrochloride (HCL) 0.5% will be expanded. An 18-gauge bevel needle will be introduced through the capsular pocket at 1 to 2cm proximal to the adductor tubercle at the proximal border of the posteromedial femoral condyle. The needle will be angled proximally and posteriorly, and then advanced to contact the posteromedial capsule. A 20mL bolus of the study drug admixture will be administered. The remaining 20mL of the study drug admixture will be administered to the anterior and lateral knee structures with approximately 1 to 1.5mL administered with each stick to the intended area.

Study Details

This is a case series to assess the clinical utility of an Intra-articular Posteromedial Surgeon Administered (IPSA) Block in patients undergoing primary unilateral total knee arthroplasty.

Key Dates

Start date
May 20, 2024
Status verified
Sep 2024
Primary completion
May 20, 2025
Completion
Dec 31, 2025

Study Design

Enrollment
10 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Experimental Group
    Patients will receive an EXPAREL IPSA block intraoperatively.

Primary Outcome Measure

Pain Assessment - 24hr recall [ Time Frame: Study Enrollment, Post-operative Day 1, Post-operative Day 2, Post-operative Day 3, Post-operative Day 14, Post-operative Day 42 ]

Locations (1)

FacilityCityStateZIPSite coordinators
Campbell ClinicGermantownTennessee38138-

Find similar trials in Germantown, TN

By research site
Campbell Clinic· Germantown, TN

Related Studies